Adipose Tissue: A Key Target for Diabetes Pathophysiology and Treatment?

Abstract

Excess adipose tissue brings with it a number of adverse consequences, many of which may stem from the development of insulin resistance. An emerging view is that inflammatory changes occurring in expanding adipose tissue are associated with the secretion of peptide and other factors that can adversely affect metabolic processes in other key insulin-target tissues, especially liver and skeletal muscle. However, there is still a commonly-expressed view that the adverse changes in other tissues are ultimately due to an excess of fatty acids, liberated by a metabolically-challenged adipose tissue. Our own studies of adipose tissue metabolism and physiological function (especially blood flow) in vivo suggest that these two views of adipose tissue function may be closely linked. Enlarged adipocytes are less dynamic in their responses, just as ‘enlarged adipose tissue’ is less dynamic in blood flow regulation. Adipocytes seem to be able to sense the appropriate level of fat storage. If the normal mechanisms regulating adipocyte fat storage are interfered with (either in genetically-modified animals or by increasing the size of the adipocytes), then perhaps some sort of cellular stress sets in, leading to the inflammatory and endocrine changes. Some evidence for this comes from the effects of the thiazolidinediones, which improve adipose tissue function and in parallel reduce inflammatory changes.

metabolic flexibility - fat balance - adipose tissue blood flow

References

• 1 Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.  Lancet. 1963;  1 785-789
• 2 Coppack SW, Fisher RM, Gibbons GF, Humphreys SM, MacDonough MJ, Potts JL, Frayn KN. Postprandial substrate deposition in human forearm and adipose tissues in vivo.  Clin Sci. 1990;  79 339-348
• 3 Frayn KN, Coppack SW, Fielding BA, Humphreys SM. Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose tissue in vivo: implications for the control of fat storage and fat mobilization.  Adv Enz Reg. 1995;  35 163-178
• 4 Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN. Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle.  Diabetes. 2002;  51 2684-2690
• 5 Summers LKM, Samra JS, Humphreys SM, Morris RJ, Frayn KN. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity.  Clin Sci. 1996;  91 679-683
• 6 Summers LKM, Callow J, Samra JS, Macdonald IA, Matthews DR, Frayn KN. The effect on adipose tissue blood flow of isoenergetic meals containing different amounts and types of fat.  Int J Obes. 2001;  25 1294-1299
• 7 Saleh J, Summers L, Cianflone K, Fielding B, Sniderman A, Frayn K. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period.  J Lipid Res. 1998;  39 884-891
• 8 Samra J, Giles S, Summers L, Evans R, Arner P, Humphreys S, Clark M, Frayn K. Peripheral fat metabolism during infusion of an exogenous triacylglycerol emulsion.  Int J Obesity. 1998;  22 806-812
• 9 Evans K, Clark ML, Frayn KN. Effects of an oral and intravenous fat load on adipose tissue and forearm lipid metabolism.  Am J Physiol. 1999;  276 E241-E248
• 10 Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM, Kirk MJ, Potts JL, Hockaday TDR. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal.  Metabolism. 1992;  41 264-272
• 11 Tan GD, Fielding BA, Currie JM, Humphreys SM, Désage M, Frayn KN, Laville M, Vidal H, Karpe F. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.  Diabetologia. 2005;  48 83-95
• 12 Tan GD, Neville MJ, Liverani E, Humphreys SM, Currie JM, Dennis AL, Fielding BA, Karpe F. The in vivo effects of the Pro12Ala PPARg2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank.  Diabetologia. 2006;  49 158-168
• 13 Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination.  Diabetes. 2000;  49 677-683
• 14 Kelley DE. Skeletal muscle triglycerides. An aspect of regional adiposity and insulin resistance.  Ann N Y Acad Sci. 2001;  967 135-145
• 15 Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything.  J Clin Invest. 2005;  115 1699-1702
• 16 Frayn KN. Adipose tissue as a buffer for daily lipid flux.  Diabetologia. 2002;  45 1201-1210
• 17 Abel ED, Peroni O, Kim JK, Kim Y-B, Boss O, Hadro E, Minnemann T, Shulman GI, Kahn BB. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver.  Nature. 2001;  409 729-733
• 18 Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integra-tive physiology of human adipose tissue.  Int J Obesity. 2003;  27 875-888
• 19 Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM.  Diabetologia. 1995;  38 1213-1217
• 20 Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance.  Diabetologia. 2000;  43 1498-1506
• 21 Frayn KN. Obesity and metabolic disease: is adipose tissue the culprit?.  Proc Nutr Soc. 2005;  64 7-13
• 22 Campbell PJ, Carlson MG, Nurjhan N. Fat metabolism in human obesity.  Am J Physiol. 1994;  266 E600-E605
• 23 Large V, Reynisdottir S, Langin D, Fredby K, Klannemark M, Holm C, Arner P. Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects.  J Lipid Res. 1999;  40 2059-2066
• 24 Langin D, Dicker A, Tavernier G, Hoffstedt J, Mairal A, Rydén M, Arner E, Sicard A, Jenkins CM, Viguerie N, Harmelen V van, Gross RW, Holm C, Arner P. Adipocyte lipases and defect of lipolysis in human obesity.  Diabetes. 2005;  54 3190-3197
• 25 Samra JS, Simpson EJ, Clark ML, Forster CD, Humphreys SM, Macdonald IA, Frayn KN. Effects of epinephrine infusion on adipose tissue: interactions between blood flow and lipid metabolism.  Am J Physiol. 1996;  271 E834-E839
• 26 Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.  J Clin Endocrinol Metab. 1994;  78 717-721
• 27 Kumar S, Durrington PN, Bhatnagar D, Laing I. Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome.  Lancet. 1994;  343 1073-1074
• 28 Davoren PM, Alberti KGMM. The effect of 24-hour suppression of plasma non-esterified fatty acid levels on glucose and lipid metabolism in NIDDM.  Diab Nutr Metab. 1995;  8 17-23
• 29 Karpe F, Frayn KN. The nicotinic acid receptor-a new mechanism for an old drug.  Lancet. 2004;  363 1892-1894
• 30 Oakes ND, Thalén PG, Jacinto SM, Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.  Diabetes. 2001;  50 1158-1165
• 31 Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.  J Clin Invest. 1998;  101 1354-1361
• 32 Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U. The effect of PPARgamma ligands on the adipose tissue in insulin resistance.  Prostaglandins Leukot Essent Fatty Acids. 2005;  73 65-75
• 33 Buckingham RE. Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection.  Hepatology Res. 2005;  33 167-170
• 34 Chu JW, Abbasi F, Lamendola C, MacLaughlin T, Reaven GM, Tsao PS. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects.  Diab Vasc Dis Res. 2005;  2 37-41
• 35 Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM. Regulation of muscle fiber type and running endurance by PPARd.  Plos Biology. 2004;  2 1532-1539
• 36 Oliver Jr WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.  Proc Natl Acad Sci USA. 2001;  98 5306-5311
• 37 Barish GD, Narkar VA, Evans RM. PPARd: a dagger in the heart of the metabolic syndrome.  J Clin Invest. 2006;  116 590-597
• 38 Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LKM, Frayn KN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity.  Diabetes. 2002;  51 2467-2473
• 39 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419

Correspondence